- 5 years ago


Vancouver’s Zymeworks announced today the completion of a $8.1 Million financing round. The financing consists of a follow-on round of institutional investment by Montreal’s CTI Life Sciences Fund, as well as a new investment by Advanced Biotechnologies Venture Fund and investments by several existing private shareholders.

Zymeworks will use the proceeds to advance its Azymetric and AlbuCORE platforms, as well as the development of Zymeworks’ best-in-class protein therapeutics pipeline in the areas of cancer, autoimmunity and inflammatory diseases.